Bristol-Myers Squibb Signals Confident Path After Q1 Call

Bristol-Myers Squibb Company ((BMY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Bristol-Myers Squibb’s latest earnings call struck a cautiously optimistic tone, as management emphasized broad momentum in its growth portfolio and several standout product performances against a backdrop of margin pressure and legacy-drug erosion. Executives framed the quarter as proof the company can fund innovation and shareholder returns while absorbing near-term headwinds and clinical-event risk in 2026.

Total Revenue Growth and Top-Line Outlook

Total revenue in the first quarter of 2026 reached about $11.5 billion, a modest 1% increase year-over-year that nonetheless kept the company on pace for its full-year plan. Management stressed that the business is tracking toward the upper end of revenue guidance, suggesting confidence in both demand trends and execution.

Growth Portfolio Performance Drives the Story

The growth portfolio remained the engine of Bristol-Myers Squibb’s narrative, delivering 9% year-over-year sales growth to $6.2 billion. Leadership highlighted a broad set of contributors, including Reblozyl, Breyanzi, Opdualag, Qvantig and Cobenfy, and described this diversified strength as in line with expectations.

Eliquis Strength Amid Pricing Changes

Eliquis continued to be a cornerstone asset with revenue of roughly $4.1 billion, up 13% from a year ago despite U.S. list price reductions. Management pointed to resilient demand and strong underlying usage, underscoring Eliquis’ role in supporting both near-term earnings and funding for pipeline investment.

Breyanzi Momentum in Cell Therapy

Breyanzi posted a standout quarter with 53% growth, reflecting what the company called a best-in-class profile in its approved cell therapy indications. Executives emphasized “continued strong demand” and suggested that broader adoption and label expansion could keep Breyanzi as a key growth lever.

Reblozyl and Sotyktu Extend the Growth Base

Reblozyl grew 15% year-over-year, supported by uptake across multiple lines of anemia associated with myelodysplastic syndromes. Sotyktu added to the growth story with 20% global revenue expansion and a recent approval in psoriatic arthritis, which management expects will further broaden its commercial footprint.

Camzyos Rapid Adoption, With Emerging Competition

Camzyos revenue nearly doubled to $314 million in the quarter, fueled by strong patient starts and persistency, with about 25,000 U.S. patients treated to date. While the launch remains robust, management acknowledged a new competitor in obstructive HCM, making differentiation through REMS processes and execution an operational priority.

Qvantig Conversion Highlights Subcutaneous Opportunity

Qvantig, the company’s subcutaneous auto-injector, has converted more than 10% of the relevant U.S. IV business in just over a year, signaling solid physician and patient uptake. Management laid out an ambitious goal of converting roughly 30% to 40% of the IV franchise over the next two years, framing Qvantig as both a growth and margin lever.

Pipeline and Regulatory Milestones Underpin Future Growth

The quarter brought notable R&D wins, including FDA acceptance of iberdomide with Breakthrough Therapy status and priority review, with a key decision expected in August. Positive Phase III interim results for mezignomide in lymphoma and for an ADC in triple-negative breast cancer, along with multiple new approvals and readouts, reinforced confidence in the late-stage pipeline.

R&D Productivity and Cost Savings Targets

Bristol-Myers Squibb is investing heavily in R&D infrastructure and AI with the goal of identifying lead molecules about 50% faster and cutting development cycle times by around 30% versus a few years ago. Management reiterated that it remains on track to deliver the remaining $2 billion in strategic productivity savings by the end of 2027, supporting profitability despite pricing and mix pressures.

Strong Balance Sheet and Cash Generation

The company ended March with approximately $11 billion in cash and marketable securities and generated about $1.1 billion in operating cash flow in the quarter. This financial strength gives Bristol-Myers Squibb flexibility for business development, continued investment in its pipeline and ongoing dividend payments.

Opdivo Decline and Inventory Dynamics

Not all trends were favorable: Opdivo revenue fell 8% year-over-year to roughly $2.1 billion, primarily driven by a U.S. wholesaler inventory drawdown that left stocks at the low end of typical ranges. Management framed this as largely a timing issue but noted it is closely watching how inventory levels normalize in coming quarters.

Gross Margin Pressure from Product Mix

Non-GAAP gross margin declined 280 basis points to 70.3%, reflecting a less favorable product mix as newer therapies and pricing shifts weigh on margins. Executives signaled that productivity initiatives and portfolio evolution should help offset some of this pressure over time, but investors should expect ongoing mix-related volatility.

Legacy Portfolio Headwinds and Generics

Growth from newer products continued to be partially offset by increased generic competition across several legacy brands, dampening overall top-line expansion. Management acknowledged that erosion in the mature portfolio remains a structural headwind, reinforcing the importance of the growth portfolio and pipeline to sustain future earnings.

Eliquis Price Reduction and Cash Flow Mechanics

The U.S. list price reduction for Eliquis, implemented at the start of the year, prompted a wholesale inventory build and roughly $1.2 billion in lower net cash collections in the quarter. The company expects this to reverse over the remainder of the year as lower rebate payments flow through, suggesting that the impact is more timing-related than structural.

Dependence on Late-Stage Readouts and Binary Risk

Looking out to late 2026, Bristol-Myers Squibb is heavily reliant on several pivotal readouts, including milvexian in AFib and stroke prevention, Cobenfy in Alzheimer’s psychosis, iberdomide PFS data and Admilparant in fibrotic lung disease. Management underscored that these programs are critical to the long-term growth profile, but they also introduce material execution and binary clinical risk.

Forward-Looking Guidance and Management Outlook

Management reaffirmed full-year 2026 guidance and said the business is tracking toward the upper end of revenue and EPS ranges after a solid first quarter. Alongside robust growth-portfolio trends and strong cash and cost-control metrics, leadership reiterated its confidence in hitting $2 billion of remaining productivity savings by 2027 and in improving R&D efficiency to support future launches.

Bristol-Myers Squibb’s earnings call portrayed a company balancing strong momentum in key growth assets with real but manageable headwinds from margins, generics and product transitions. For investors, the story hinges on continued execution in the growth portfolio, disciplined cost management and successful delivery of a packed slate of late-stage clinical milestones over the next few years.